arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Coya Therapeutics, Inc.

COYA

$5.05 ▼ -0.25 (-4.81%) at close

6 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Coya Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $84.5M

Dividend Yield —

Revenue Growth 123.6% ↗

Op. Margin -283.9% ↗

ROIC -52.4% ↘

FCF / Share $-0.64 ↗

Trailing P/E —

Price / Book 2.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$7.95M

↑ +123.6% —

Net Income Profit after all expenses

$-21.23M

↓ -42.6% —

Operating Margin Operating profit as % of sales

-283.9%

↑ +41.5% 0th

FCF / Share Free cash flow per share

$-0.64

↑ +4.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	123.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1445%)	-40.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-610%)	—	—	—	—
EPS Growth YoY (%)	-29.6% Weak → Weak Stable Year-over-year change in earnings per share Optimal: > 10%	-24.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	83.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-150.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-42.6% Weak ↑ Weak Improving Year-over-year change in net income	-86.3% Weak ↓ Weak Declining Year-over-year change in net income	34.8% Excellent Excellent Year-over-year change in net income	-150.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	4.9% Caution ↑ Caution Improving Year-over-year change in free cash flow	38.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	60.6% Excellent Excellent Year-over-year change in free cash flow	-85.4% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	-283.9% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1992%)	-485.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3336%)	-131.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-978%)	—	—	—
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	4.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-10.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-267.1% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2326%)	-418.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3589%)	-133.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1209%)	—	—	—
FCF Margin (%) (%)	-135.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-289.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-186.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.51x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.40x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-52.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	116.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-105.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-45.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-38.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-116.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-101.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-49.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-429%)	-37.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-351%)	-22.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-249%)	145.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+873%)	-134.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-995%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-46.82M	$-38.34M	$-32.63M	$-5.93M	$-4.34M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.47	$0.23	$0.59	$0.00	—	—
Basic EPS, GAAP (USD)	$-1.27	$-0.98	$-0.79	$-4.73	$-1.89	—
Free Cash Flow per Share (USD)	$-0.64	$-0.68	$-1.10	$-2.79	$-1.51	—
Book Value per Share (USD)	$2.06	$2.37	$2.47	$-3.24	$1.41	—
Tangible Book Value per Share (USD)	$2.06	$2.37	$2.47	$-3.24	$1.41	—
Basic Weighted Avg Shares (shares)	16.73M	15.24M	10.16M	2.59M	2.59M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$44.07M	$40.48M	$36.14M	$3.36M	$3.44M	—
Total Equity (USD)	$43.03M	$39.58M	$35.64M	$-8.39M	$3.64M	$8.30M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$7.95M	$3.55M	$6.00M	$0.00	—	—
Depreciation Expense (USD)	$27.36K	$27.36K	$27.36K	$27.36K	$16.13K	—
Net Income, GAAP (USD)	$-21.23M	$-14.88M	$-7.99M	$-12.24M	$-4.89M	—
Operating Cash Flow (USD)	$-10.74M	$-10.29M	$-11.19M	$-7.24M	$-3.90M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 20 quarters

Coya Therapeutics, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare COYA with peers